Xiapex approved by the EU Commission for the treatment of Peyronie's disease

Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that the EU Commission has approved Xiapex® (collagenase clostridium histolyticum) for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. Peyronie's disease is a condition that involves the development of collagen plaque, or scar tissue, on the shaft of the penis.

Read more

Sobi extends and restructures distribution agreement with Exelixis for Cometriq

Swedish Orphan Biovitrum AB (Sobi) (STO: SOBI) today announced that their agreement with Exelixis, Inc. has been restructured and extended to 31 December 2019. Sobi is responsible for the commercialisation and distribution of Cometriq® (cabozantinib) for progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC) in the European Union (EU), Switzerland, Norway, Russia, and Turkey. The companies established the collaboration in February 2013, which was initially structured to expire 31 December 2015.

Read more